Cargando…

The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery

PURPOSE: This article aimed to study the prognostic value of preoperative plasma fibrinogen and CA19-9 in non-distant metastatic breast cancer (BC). PATIENTS AND METHODS: A total of 343 non-distant metastatic BC patients were included in this study. The optimal cut-off values of plasma fibrinogen an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenjing, Zheng, Chen, Quan, Ruida, Dai, Xuanxuan, Zhang, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520160/
https://www.ncbi.nlm.nih.gov/pubmed/33061583
http://dx.doi.org/10.2147/CMAR.S270385
_version_ 1783587724533432320
author Hu, Wenjing
Zheng, Chen
Quan, Ruida
Dai, Xuanxuan
Zhang, Xiaohua
author_facet Hu, Wenjing
Zheng, Chen
Quan, Ruida
Dai, Xuanxuan
Zhang, Xiaohua
author_sort Hu, Wenjing
collection PubMed
description PURPOSE: This article aimed to study the prognostic value of preoperative plasma fibrinogen and CA19-9 in non-distant metastatic breast cancer (BC). PATIENTS AND METHODS: A total of 343 non-distant metastatic BC patients were included in this study. The optimal cut-off values of plasma fibrinogen and CA19-9 were obtained by receiver operating characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analyses were used to evaluate prognostic factors for overall survival (OS). Survival data were assessed using Kaplan–Meier survival analysis with the Log-rank test. Based on the cut-off values, we classified the fibrinogen-CA19-9 score as follows: 2 (both hyperfibrinogenemia and high CA19-9), 1 (either hyperfibrinogenemia or high CA19-9), and 0 (neither hypefibrinogenemia nor high CA19-9). RESULTS: Our follow-up time totaled 10 years, the median follow-up time was 77 months (range=2–119 months), and 82 (23.9%) of 343 patients died during the follow-up period. The optimal cut-off values of plasma fibrinogen and CA19-9 were 2.805 g/L and 11.85 U/mL, respectively. The multivariate Cox analysis results suggested that there was a significant association between worse OS and elevated preoperative plasma fibrinogen and CA19-9 levels (HR=2.016, 95% CI=1.216–3.342, P=0.007; and HR=2.042, 95% CI=1.282–3.253, P=0.003). The area under the ROC curve (AUC) increased from 0.589 (for plasma fibrinogen) and 0.594 (for CA19-9) to 0.640 when these two parameters were combined. When we added this combined factor to the multivariate analysis, it was an independent prognostic factor for BC (P<0.001). According to the above results, we chose four prognostic factors to construct our nomogram. The AUC was 0.724, which indicates that the nomogram performs well. CONCLUSION: The combination of plasma fibrinogen and CA19-9 could be used as a valid independent prognostic factor for non-distant metastatic BC compared with either parameter alone and could easily be applied in clinical practice.
format Online
Article
Text
id pubmed-7520160
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75201602020-10-14 The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery Hu, Wenjing Zheng, Chen Quan, Ruida Dai, Xuanxuan Zhang, Xiaohua Cancer Manag Res Original Research PURPOSE: This article aimed to study the prognostic value of preoperative plasma fibrinogen and CA19-9 in non-distant metastatic breast cancer (BC). PATIENTS AND METHODS: A total of 343 non-distant metastatic BC patients were included in this study. The optimal cut-off values of plasma fibrinogen and CA19-9 were obtained by receiver operating characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analyses were used to evaluate prognostic factors for overall survival (OS). Survival data were assessed using Kaplan–Meier survival analysis with the Log-rank test. Based on the cut-off values, we classified the fibrinogen-CA19-9 score as follows: 2 (both hyperfibrinogenemia and high CA19-9), 1 (either hyperfibrinogenemia or high CA19-9), and 0 (neither hypefibrinogenemia nor high CA19-9). RESULTS: Our follow-up time totaled 10 years, the median follow-up time was 77 months (range=2–119 months), and 82 (23.9%) of 343 patients died during the follow-up period. The optimal cut-off values of plasma fibrinogen and CA19-9 were 2.805 g/L and 11.85 U/mL, respectively. The multivariate Cox analysis results suggested that there was a significant association between worse OS and elevated preoperative plasma fibrinogen and CA19-9 levels (HR=2.016, 95% CI=1.216–3.342, P=0.007; and HR=2.042, 95% CI=1.282–3.253, P=0.003). The area under the ROC curve (AUC) increased from 0.589 (for plasma fibrinogen) and 0.594 (for CA19-9) to 0.640 when these two parameters were combined. When we added this combined factor to the multivariate analysis, it was an independent prognostic factor for BC (P<0.001). According to the above results, we chose four prognostic factors to construct our nomogram. The AUC was 0.724, which indicates that the nomogram performs well. CONCLUSION: The combination of plasma fibrinogen and CA19-9 could be used as a valid independent prognostic factor for non-distant metastatic BC compared with either parameter alone and could easily be applied in clinical practice. Dove 2020-09-23 /pmc/articles/PMC7520160/ /pubmed/33061583 http://dx.doi.org/10.2147/CMAR.S270385 Text en © 2020 Hu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hu, Wenjing
Zheng, Chen
Quan, Ruida
Dai, Xuanxuan
Zhang, Xiaohua
The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
title The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
title_full The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
title_fullStr The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
title_full_unstemmed The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
title_short The Prognostic Value of Combination of Plasma Fibrinogen and CA19-9 in Non-Distant Metastatic Breast Cancer Patients Undergoing Surgery
title_sort prognostic value of combination of plasma fibrinogen and ca19-9 in non-distant metastatic breast cancer patients undergoing surgery
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520160/
https://www.ncbi.nlm.nih.gov/pubmed/33061583
http://dx.doi.org/10.2147/CMAR.S270385
work_keys_str_mv AT huwenjing theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT zhengchen theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT quanruida theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT daixuanxuan theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT zhangxiaohua theprognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT huwenjing prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT zhengchen prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT quanruida prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT daixuanxuan prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery
AT zhangxiaohua prognosticvalueofcombinationofplasmafibrinogenandca199innondistantmetastaticbreastcancerpatientsundergoingsurgery